Edition:
India

Kala Pharmaceuticals Inc (KALA.OQ)

KALA.OQ on NASDAQ Stock Exchange Global Select Market

16.04USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$16.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
96,856
52-wk High
$26.74
52-wk Low
$11.81

Latest Key Developments (Source: Significant Developments)

Kala Pharmaceuticals Posts Q4 Loss Per Share $0.46
Monday, 26 Mar 2018 

March 26 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.46.Q4 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.ENDED 2017 WITH $114.6 MILLION IN CASH.PDUFA TARGET ACTION DATE FOR INVELTYS IS AUGUST 24, 2018.  Full Article

Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals
Saturday, 13 Jan 2018 

Jan 12 (Reuters) - Kala Pharmaceuticals Inc ::ORBIMED ADVISORS LLC REPORTS ABOUT 11 PERCENT PASSIVE STAKE IN KALA PHARMACEUTICALS INC AS OF JAN 10.  Full Article

Kala Pharmaceuticals Announces Topline Results For Two Phase 3 Trials Of Kpi-121
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FOR TWO PHASE 3 TRIALS (STRIDE 1 AND STRIDE 2) OF KPI-121 0.25% IN DRY EYE DISEASE.KALA PHARMACEUTICALS INC - KPI-121 0.25% WAS WELL-TOLERATED WITH ELEVATIONS IN IOP SIMILAR TO PLACEBO.KALA PHARMACEUTICALS INC - IN STRIDE 1 TRIAL, STATISTICAL SIGNIFICANCE WAS ACHIEVED FOR PRIMARY SIGN ENDPOINT.KALA PHARMACEUTICALS- OCULAR DISCOMFORT SEVERITY AT DAY 15 IN ITT POPULATION SHOWED IMPROVEMENT BUT DID NOT REACH STATISTICAL SIGNIFICANCE IN STRIDE 2.KALA PHARMACEUTICALS INC - IN STRIDE 2 TRIAL, STATISTICAL SIGNIFICANCE WAS ACHIEVED FOR PRIMARY SIGN ENDPOINT.KALA PHARMACEUTICALS INC - WILL CONTINUE TO ANALYZE RESULTS OF BOTH PHASE 3 TRIALS.  Full Article

Kala Pharmaceuticals Announces NDA For Inveltystm Accepted By U.S. FDA
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES NEW DRUG APPLICATION FOR INVELTYSTM (KPI-121 1%) HAS BEEN ACCEPTED FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION.KALA PHARMACEUTICALS INC - BRAND NAME FOR KPI-121 1%, INVELTYS, HAS BEEN CONDITIONALLY APPROVED BY FDA.KALA PHARMA-FDA INDICATES APPLICATION FOR INVELTYSTM SUFFICIENTLY COMPLETE TO PERMIT SUBSTANTIVE REVIEW,SET PDUFA TARGET ACTION DATE OF AUGUST 24,2018​.  Full Article

Kala Pharmaceuticals reports Q3 loss per share $0.56
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Kala Pharmaceuticals Inc :Kala Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.56.Kala Pharmaceuticals - ‍Top-line results from phase 3 clinical program for KPI-121 0.25% in patients with dry eye disease are expected by end of 2017​.Kala Pharmaceuticals Inc - ‍Expects that its existing cash on hand will enable it to fund operations through Q2 of 2019​.  Full Article

Kala Pharmaceuticals submits new drug application for Inveltystm
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Kala Pharmaceuticals Inc :Kala pharmaceuticals submits new drug application to U.S. Food and Drug Administration for Inveltystm (KPI-121 1 pct).  Full Article

Hadley Harbor Master Investors (Cayman) L.P. reports 7.45 pct passive stake in Kala Pharmaceuticals Inc
Monday, 31 Jul 2017 

July 31 (Reuters) - Kala Pharmaceuticals Inc ::Hadley Harbor Master Investors (Cayman) L.P. reports 7.45 percent passive stake in Kala Pharmaceuticals Inc as on July 20, 2017 - Sec Filing‍​.  Full Article

Kala Pharma sees IPO of 6 mln shares priced between $14-$16/shr
Monday, 10 Jul 2017 

July 10 (Reuters) - Kala Pharmaceuticals Inc ::Kala Pharmaceuticals sees IPO of 6 million shares of co's common stock priced between $14.00 and $16.00 per share.  Full Article

BRIEF-Kala Pharmaceuticals Posts Q4 Loss Per Share $0.46

* KALA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS